P. Ghatage

发表

Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND.116).

E. Eisenhauer, A. Oza, K. Swenerton, 2003, Gynecologic oncology.

Phase II study of oral ridaforolimus in women with recurrent or metastatic endometrial cancer.

H. Mackay, E. Eisenhauer, A. Oza, 2014, Gynecologic oncology.

Patient-Reported Symptom Burden Near the End of Life in Patients With Gynaecologic Cancers.

P. Ghatage, Nilanchali Singh, A. Batra, 2020, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

PIK3CA mutational status and overall survival in patients with cervical cancer treated with radical chemoradiotherapy.

M. Köbel, S. Lees-Miller, P. Ghatage, 2013, Gynecologic oncology.

A phase II trial of pemetrexed in combination with carboplatin in patients with recurrent ovarian or primary peritoneal cancer.

T. Bauknecht, J. Sehouli, P. Ghatage, 2012, Gynecologic oncology.

Progression-free survival in advanced ovarian cancer: a Canadian review and expert panel perspective.

M. Buyse, H. Mackay, A. Oza, 2011, Current oncology.

Use of systemic therapy in women with recurrent ovarian cancer--development of a national clinical practice guideline.

G. Browman, L. Elit, P. Ghatage, 2007, Gynecologic oncology.

Human kallikrein related peptidases 6 and 13 in combination withCA125 is a more sensitive test for ovarian cancer than CA125 alone.

G. Yousef, J. Doré, P. Ghatage, 2009, Cancer biomarkers : section A of Disease markers.

Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial

H. Putter, C. Haie-meder, H. Kitchener, 2018, The Lancet. Oncology.

Primary carcinoma of the rectovaginal septum diagnosed as uterine prolapse.

P. Ghatage, M. Duggan, T. Mainprize, 2005, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Association of Hormone Receptor Expression with Survival in Ovarian Endometrioid Carcinoma: Biological Validation and Clinical Implications

M. Köbel, L. Kelemen, P. Ghatage, 2017, International journal of molecular sciences.

Low-Grade Serous Carcinoma – The Clinical Challenge

M. Köbel, P. Ghatage, G. Nelson, 2015 .

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

E. Eisenhauer, A. Oza, D. Provencher, 2010, Journal of the National Cancer Institute.

Phase II study of erlotinib in recurrent or metastatic endometrial cancer: NCIC IND-148.

E. Eisenhauer, A. Oza, D. Provencher, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Informatics and Ovarian Cancer Care

B. Rosen, L. Elit, P. Ghatage, 2009 .

Safety and dose modification for patients receiving niraparib

J. Ledermann, J. Berek, I. Vergote, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Clinical Performance of the PreTect HPV-Proofer E6/E7 mRNA Assay in Comparison with That of the Hybrid Capture 2 Test for Identification of Women at Risk of Cervical Cancer

P. Ghatage, F. Coutlée, V. Gadag, 2010, Journal of Clinical Microbiology.

The Effects of Anemia and Blood Transfusion on Patients With Stage III-IV Ovarian Cancer

P. Ghatage, Xiao-qing Liu, A. Altman, 2013, International Journal of Gynecologic Cancer.

Examining Survival Outcomes of 852 Women With Advanced Ovarian Cancer: A Multi-institutional Cohort Study

B. Rosen, J. McGee, Wei Xu, 2018, International Journal of Gynecologic Cancer.

A Comparison of Survival Outcomes in Advanced Serous Ovarian Cancer Patients Treated With Primary Debulking Surgery Versus Neoadjuvant Chemotherapy

B. Rosen, S. Narod, J. Kotsopoulos, 2017, International Journal of Gynecologic Cancer.

Optimal debulking targets in women with advanced stage ovarian cancer: a retrospective study of immediate versus interval debulking surgery.

P. Ghatage, A. Altman, G. Nelson, 2012, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.

M. Köbel, S. Lees-Miller, P. Ghatage, 2020, Gynecologic oncology.

Dose-dense paclitaxel with carboplatin for advanced ovarian cancer: a feasible treatment alternative.

P. Ghatage, S. Glaze, G. Nelson, 2013, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Intraperitoneal chemotherapy for advanced ovarian and peritoneal cancers in patients following interval debulking surgery or primary cytoreductive surgery: Tom Baker Cancer Centre experience from 2006 to 2009.

P. Ghatage, J. Nation, P. Chu, 2010, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Pharmacotherapeutic treatment options for recurrent epithelial ovarian cancer

P. Ghatage, Nilanchali Singh, A. Jayraj, 2022, Expert opinion on pharmacotherapy.

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers

A. Tinker, A. Oza, D. Provencher, 2022, Current oncology.

Past, Present, and Future of Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer

P. Ghatage, Nilanchali Singh, Mona Mishra, 2021, Cureus.

Performance of proex c and pretect hpv‐proofer e6/e7 mrna tests in comparison with the hybrid capture 2 hpv dna test for triaging ascus and lsil cytology

P. Ghatage, R. Alaghehbandan, F. Coutlée, 2013, Diagnostic cytopathology.

Uterine Sarcoma and Aromatase Inhibitors: Tom Baker Cancer Centre Experience and Review of the Literature

P. Ghatage, A. Altman, G. Nelson, 2012, International Journal of Gynecologic Cancer.

Management of EMA-CO resistant/refractory gestational trophoblastic neoplasia

P. Ghatage, Abdulaziz Babaier, Brent Jim, 2018 .

p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial

P. Pollock, C. Genestie, H. Kitchener, 2022, Modern Pathology.

Management of Gynecologic Cancer During COVID-19 Pandemic: South Asian Perspective

P. Ghatage, Nilanchali Singh, N. Mishra, 2022, Cancer control : journal of the Moffitt Cancer Center.

Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study

Yurii B. Shvetsov, M. Beckmann, A. Talhouk, 2022, British Journal of Cancer.

A rare case of NUT midline carcinoma.

M. Köbel, P. Ghatage, S. Glaze, 2012, Gynecologic oncology case reports.

Re: "A low-grade ovarian carcinoma case with coincident LOH of PTCH1 and BRCA1, and a mutation in BRCA1," Int J Gyn Pathol 2012 May;31: 264-271.

M. Köbel, P. Ghatage, 2013, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Long-term toxicity and health-related quality of life after adjuvant chemoradiotherapy or radiotherapy alone for high-risk endometrial cancer in the randomised PORTEC-3 trial.

H. Putter, C. Haie-meder, H. Kitchener, 2020, International journal of radiation oncology, biology, physics.

Prognostic and theragnostic biomarkers in ovarian clear cell carcinoma.

K. Wiedemeyer, M. Köbel, M. Anglesio, 2020, medRxiv.

Ten years experience in the management of borderline ovarian tumors at Tom Baker Cancer Centre

P. Ghatage, N. Anfinan, K. Sait, 2011, Archives of Gynecology and Obstetrics.

Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

A. Whittemore, M. Beckmann, P. Fasching, 2017, JAMA oncology.

Treatment Options in Vulvar Lichen Sclerosus: A Scoping Review

P. Ghatage, Nilanchali Singh, N. Mishra, 2021, Cureus.

Human papillomavirus types 16 and 18 sequences in early cervical neoplasia.

P. Ghatage, M. M. Pater, A. Pater, 1986, Virology.

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

Yurii B. Shvetsov, A. Whittemore, M. Beckmann, 2020, British Journal of Cancer.

Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2)

A. Tinker, A. Oza, D. Provencher, 2021, Nature Communications.

Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial

James X. Sun, A. Oza, D. Provencher, 2017, The Lancet.

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

B. Monk, I. Vergote, A. Makhson, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8+ TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas

Yurii B. Shvetsov, Kylie L. Gorringe, A. Talhouk, 2021, The Journal of pathology.

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma

Yurii B. Shvetsov, Kylie L. Gorringe, A. Talhouk, 2021, medRxiv.

CCNE1 and survival of patients with tubo‐ovarian high‐grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study

Yurii B. Shvetsov, M. Pike, A. Talhouk, 2022, Cancer.

Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study

Sebastian M. Armasu, A. Whittemore, P. Fasching, 2018, The journal of pathology. Clinical research.

Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study

M. Beckmann, P. Fasching, R. Vierkant, 2014, British Journal of Cancer.

The diagnostic utility of TP53 and CDKN2A to distinguish ovarian high-grade serous carcinoma from low-grade serous ovarian tumors

M. Köbel, S. Kalloger, D. Capper, 2013, Modern Pathology.

Quantification of ER/PR expression in ovarian low-grade serous carcinoma.

M. Köbel, S. Kalloger, P. Ghatage, 2013, Gynecologic oncology.

Phosphatidyl inositol-3 kinase (PIK3CA) E545K mutation confers cisplatin resistance and a migratory phenotype in cervical cancer cells

Chen Wang, Shujuan Fang, P. Ghatage, 2016, Oncotarget.

PIK3CA missense mutation is associated with unfavorable outcome in grade 3 endometrioid carcinoma but not in serous endometrial carcinoma.

M. Köbel, P. Ghatage, C. Doll, 2014, Gynecologic oncology.

Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group.

H. Mackay, E. Eisenhauer, A. Oza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II study of sagopilone (ZK-EPO) plus carboplatin in women with recurrent platinum-sensitive ovarian cancer

P. Ghatage, P. Celano, S. McMeekin, 2011, British Journal of Cancer.

A Clinical and Molecular Phase II Trial of Oral ENMD-2076 in Ovarian Clear Cell Carcinoma (OCCC): A Study of the Princess Margaret Phase II Consortium

A. Tinker, A. Oza, B. Clarke, 2018, Clinical Cancer Research.

Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium

Yurii B. Shvetsov, A. Whittemore, A. Talhouk, 2020, British Journal of Cancer.

Enhanced Recovery After Surgery (ERAS) in gynecologic oncology: System-wide implementation and audit leads to improved value and patient outcomes.

P. Faris, P. Ghatage, S. Glaze, 2018, Gynecologic oncology.

Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study

A. Tinker, Jubilee Brown, P. Ghatage, 2022, Journal for ImmunoTherapy of Cancer.

Phase II Trial of Cabozantinib in Recurrent/Metastatic Endometrial Cancer: A Study of the Princess Margaret, Chicago, and California Consortia (NCI9322/PHL86)

D. Matei, A. Oza, M. Tsao, 2020, Clinical Cancer Research.

Postoperative chemotherapy in advanced ovarian granulosa cell tumors

P. Ghatage, G. Stuart, A. Schepansky, 2001, International Journal of Gynecologic Cancer.

Policy Statement: Guidelines for the Laparoscopic Management of the Adnexal Mass

P. Ghatage, M. Plante, T. Ehlen, 1998 .

Patients and Methods: a Candidate Array Was Designed Based on the Breast Cancer Information Core Database For

B. Monk, R. Favis, P. Ghatage, 2022 .

Sexual Dysfunction in Cervical Cancer Survivors: A Scoping Review

P. Ghatage, Nilanchali Singh, N. Mishra, 2021, Women's health reports.

Cervical Cancer Prevention in Low-Resource Settings

Dianne Miller, J. McAlpine, L. Elit, 2011 .

Impact of transversus abdominis plane blocks versus non-steroidal anti-inflammatory on post-operative opioid use in ERAS ovarian cancer surgery

G. Fitzmaurice, P. Ghatage, S. Glaze, 2019, International Journal of Gynecological Cancer.

Low-Grade Serous Carcinoma of the Ovary: The Current Status

P. Ghatage, W. Alselwi, Abdulaziz Babaier, 2022, Diagnostics.

Aptima HPV E6/E7 mRNA Test Is as Sensitive as Hybrid Capture 2 Assay but More Specific at Detecting Cervical Precancer and Cancer

P. Ghatage, F. Coutlée, V. Gadag, 2010, Journal of Clinical Microbiology.

MyD88 and TLR4 Expression in Epithelial Ovarian Cancer

A. Whittemore, P. Fasching, R. Vierkant, 2018, Mayo Clinic proceedings.

Association of Ipilimumab With Safety and Antitumor Activity in Women With Metastatic or Recurrent Human Papillomavirus–Related Cervical Carcinoma

A. Tinker, H. Mackay, A. Oza, 2017, JAMA oncology.

Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada

E. Franco, A. Ferenczy, P. Ghatage, 2011, Journal of medical virology.

Anemia, leukocytosis and thrombocytosis as prognostic factors in patients with cervical cancer treated with radical chemoradiotherapy: A retrospective cohort study

S. Lees-Miller, P. Ghatage, C. Doll, 2017, Clinical and translational radiation oncology.

Phase II study of oral ridaforolimus in patients with metastatic and/or locally advanced recurrent endometrial cancer: NCIC CTG IND 192.

H. Mackay, E. Eisenhauer, A. Oza, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Adjuvant chemoradiotherapy versus radiotherapy alone in women with high-risk endometrial cancer (PORTEC-3): patterns of recurrence and post-hoc survival analysis of a randomised phase 3 trial

H. Putter, C. Haie-meder, H. Kitchener, 2019, The Lancet. Oncology.

Interim analysis of the immune-related endpoints of the mismatch repair deficient (dMMR) and proficient (MMRp) endometrial cancer cohorts from the GARNET study

A. Tinker, P. Ghatage, L. Duska, 2021, Gynecologic Oncology.

Use of aromatase inhibitors as first- and second-line medical therapy in patients with endometrial adenocarcinoma: a retrospective study.

P. Ghatage, A. Altman, G. Nelson, 2012, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Selection of endometrial carcinomas for p53 immunohistochemistry based on nuclear features

M. Köbel, M. Anglesio, P. Ghatage, 2021, The journal of pathology. Clinical research.

Expression of PD-L1 and presence of CD8-positive T cells in pre-treatment specimens of locally advanced cervical cancer

M. Köbel, S. Lees-Miller, P. Ghatage, 2017, Modern Pathology.

Variability in endometrial carcinoma pathology practice: opportunities for improvement with molecular classification

A. Talhouk, S. Leung, A. Tinker, 2022, Modern Pathology.

Efficacy of trebananib (AMG 386) in treating epithelial ovarian cancer

P. Ghatage, K. Al Wadi, 2016, Expert opinion on pharmacotherapy.

Randomized, double-blind, placebo-controlled phase II study of AMG 386 combined with weekly paclitaxel in patients with recurrent ovarian cancer.

B. Karlan, A. Oza, D. Provencher, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Is there a role for tirapazamine in the treatment of cervical cancer?

P. Ghatage, H. Sabagh, 2012, Expert opinion on drug metabolism & toxicology.

Etiology, Clinical Features, and Diagnosis of Vulvar Lichen Sclerosus: A Scoping Review

P. Ghatage, Nilanchali Singh, 2020, Obstetrics and gynecology international.

Expression of DNA damage response proteins in cervical cancer patients treated with radical chemoradiotherapy.

S. Lees-Miller, P. Ghatage, C. Doll, 2017, Gynecologic oncology.

Mucinous Cancer of the Ovary: Overview and Current Status

P. Ghatage, Abdulaziz Babaier, 2020, Diagnostics.

Vacuum assisted wound closures in gynaecologic surgery.

P. Ghatage, A. Altman, G. Nelson, 2011, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Urolithiasis following formation of a continent urostomy: case report and review of the literature.

P. Ghatage, G. Stuart, K. Sait, 2000, Gynecologic oncology.

A rapidly evolving landscape: immune checkpoint inhibitors in pretreated metastatic endometrial cancer

A. Tinker, N. Dhani, P. Ghatage, 2023, Therapeutic advances in medical oncology.

Significant frequency of MSH2/MSH6 abnormality in ovarian endometrioid carcinoma supports histotype‐specific Lynch syndrome screening in ovarian carcinomas

M. Köbel, L. Kelemen, P. Ghatage, 2016, Histopathology.

AMG 386: profile of a novel angiopoietin antagonist in patients with ovarian cancer

P. Ghatage, Ewan J. D. Robson, E. Robson, 2011, Expert opinion on investigational drugs.

Malignant chest wall endometriosis: a case report and literature review.

P. Ghatage, A. Magliocco, J. Nation, 2009, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

LBA36 Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET

A. Tinker, P. Ghatage, L. Duska, 2020 .

p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study

Yurii B. Shvetsov, A. Whittemore, A. Talhouk, 2023, The journal of pathology. Clinical research.

Equivalent Survival of p53 Mutated Endometrial Endometrioid Carcinoma Grade 3 and Endometrial Serous Carcinoma.

M. Köbel, B. Clarke, M. Bernardini, 2020, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study.

B. Rosen, J. McGee, Wei Xu, 2017, Gynecologic oncology.

The importance of surgical staging in women with uterine serous carcinoma: experience in a single institution reveals a survival benefit.

P. Ghatage, G. Nelson, J. Nation, 2014, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

A phase 1/2 study of ipilimumab in women with metastatic or recurrent HPV-related cervical carcinoma: A study of the Princess Margaret and Chicago N01 Consortia.

A. Tinker, H. Mackay, A. Oza, 2014 .

Factor analysis of false-negative second-look laparotomy.

P. Ghatage, R. Lotocki, G. Krepart, 1990, Gynecologic Oncology.

Architectural Patterns of Ovarian/Pelvic High-grade Serous Carcinoma

M. Köbel, S. Kalloger, P. Ghatage, 2012, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

Safety and dose modification for patients receiving niraparib.

J. Berek, I. Vergote, S. Ellard, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Prognostic and Theranostic Biomarkers in Ovarian Clear Cell Carcinoma

K. Wiedemeyer, M. Köbel, M. Anglesio, 2021, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

TP53 as a Diagnostic Aid in the Distinction of Ovarian Mucinous Borderline Tumors From Mucinous Carcinoma.

Kylie L. Gorringe, M. Köbel, P. Ghatage, 2023, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

The Impact of Gynaecological Tumour Board Rounds on Patient Care.

P. Ghatage, S. Glaze, D. Halliday, 2019, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

Distribution of human papillomavirus genotypes in cervical intraepithelial neoplasia and invasive cervical cancer in Canada

E. Franco, A. Ferenczy, P. Ghatage, 2011 .

Factors Affecting Overall Survival in Premenopausal Women With Uterine Leiomyosarcoma: A Retrospective Analysis With Long-Term Follow-Up.

P. Ghatage, Nilanchali Singh, A. Batra, 2020, Journal of obstetrics and gynaecology Canada : JOGC = Journal d'obstetrique et gynecologie du Canada : JOGC.

State of the art and up-and-coming angiogenesis inhibitors for ovarian cancer

P. Ghatage, Nilanchali Singh, Daniyah Badrun, 2020, Expert opinion on pharmacotherapy.

Advanced ovarian cancer: phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel vs carboplatin-paclitaxel.

E. Eisenhauer, A. Oza, D. Provencher, 2010, Journal of the National Cancer Institute.

76P Analysis of antitumor activity of dostarlimab by tumor mutational burden (TMB) in patients (pts) with endometrial cancer (EC) in the GARNET trial

A. Tinker, P. Ghatage, L. Duska, 2021, Annals of Oncology.

A randomized double-blind phase III trial comparing vintafolide (EC145) and pegylated liposomal doxorubicin (PLD/Doxil®/Caelyx®) in combination versus PLD in participants with platinum-resistant ovarian cancer (PROCEED) (NCT01170650)

A. Oza, D. Provencher, P. Ghatage, 2015 .

272 Dostarlimab in advanced/recurrent mismatch repair deficient/microsatellite instability high or proficient/stable endometrial cancer: the GARNET study

P. Ghatage, L. Duska, V. Boni, 2021, Endometrial cancer.

Final results of OV16, a phase III randomized study of sequential cisplatin-topotecan and carboplatin-paclitaxel (CP) versus CP in first-line chemotherapy for advanced epithelial ovarian cancer (EOC): A GCIG study of NCIC CTG, EORTC-GCG, and GEICO.

E. Eisenhauer, D. Provencher, M. Carey, 2013 .

Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.

B. Monk, R. Favis, P. Ghatage, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.